QCG
FDMT icon

Quadrant Capital Group’s 4D Molecular Therapeutics FDMT Stock Holding History

Quadrant Capital Group’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$885 Hold
95
– – ﹤0.01% 2598
2025
Q4 		$713 Hold
95
– – ﹤0.01% 2624
2025
Q3 		$826 Buy
+95
New +$568 ﹤0.01% 2573
2025
Q1 		– Sell
-463
Closed -$2.58K – 2775
2024
Q4 		$2.58K Buy
+463
New +$3.63K ﹤0.01% 2463

Other funds holding FDMT

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Quadrant Capital Group's FDMT Position: Q1 2026 in Review

Quadrant Capital Group held its 4D Molecular Therapeutics (FDMT) position steady in Q1 2026 at 95 shares worth $885. The position accounts for ﹤0.01% of the portfolio, ranked #2598.

Quadrant Capital Group first reported a position in FDMT in Q4 2024 and has held it in 4 quarters since. The position peaked at $2.58K in Q4 2024. 152 funds tracked by Wall St. Rank hold FDMT as of Q1 2026.

  • Quadrant Capital Group held 95 shares of 4D Molecular Therapeutics worth $885 as of Q1 2026.
  • Quadrant Capital Group left its 4D Molecular Therapeutics share count unchanged in Q1 2026.
  • 4D Molecular Therapeutics made up ﹤0.01% of Quadrant Capital Group's portfolio in Q1 2026, its #2598 holding.
  • Quadrant Capital Group first reported a position in 4D Molecular Therapeutics in Q4 2024 and has held it in 4 quarters since.
  • Quadrant Capital Group's 4D Molecular Therapeutics position peaked at $2.58K in Q4 2024.
  • 152 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q1 2026.

Based on Quadrant Capital Group's 13F filing for Q1 2026, filed 11 May 2026.